Baylor College of Medicine: Study to Determine Cyclosporine's Role in Treating Hospitalized COVID-19 Patients
November 24, 2020
November 24, 2020
HOUSTON, Texas, Nov. 24 (TNSRes) -- The Baylor College of Medicine issued the following news release:
Baylor College of Medicine will launch a randomized clinical trial this week to determine whether the drug cyclosporine is effective in preventing disease progression in pre-ICU hospitalized COVID-19 patients.
For about 40 years, cyclosporine has been used to prevent rejection of solid organ transplants and to treat patients with rheumatoid arthritis and psoriasis.
Baylor College of Medicine will launch a randomized clinical trial this week to determine whether the drug cyclosporine is effective in preventing disease progression in pre-ICU hospitalized COVID-19 patients.
For about 40 years, cyclosporine has been used to prevent rejection of solid organ transplants and to treat patients with rheumatoid arthritis and psoriasis.